Previous 10 | Next 10 |
NEWTON, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it...
Acer Therapeutics press release ( NASDAQ: ACER ): Q3 GAAP EPS of -$0.31 beats by $0.37 . Cash and cash equivalents were $6.4M as of September 30, 2022, compared to $12.7M as of December 31, 2021. Acer believes its cash and cash equivalents available as of September...
NEWTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported fi...
Acer Therapeutics ( NASDAQ: ACER ) said the U.S. Patent and Trademark Office (USPTO) will issue a patent for claims related to certain methods of treating vascular Ehlers-Danlos syndrome (vEDS) with celiprolol. The company added that the patent application No. 16/93...
NEWTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, tod...
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements PR Newswire Third Quarter 2022 Financial Results to be Announced in Early November DALLAS , Oct. 18, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...
$3 million awarded to University of North Carolina (UNC) to support a proposed 180-patient, randomized, placebo-controlled trial in trauma patients Proposed investigator sponsored trial to evaluate the potential for ACER-801 to reduce the frequency and severity of acute stress d...
Acer Therapeutics ( NASDAQ: ACER ) said on Wednesday it was expanding ACER-801 into a new indication, to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder. ( ACER ) is trading 3.5% higher premarket. In a study con...
Licensed exclusive worldwide rights from Emory University to patents and patent applications for certain methods of treating or preventing post-traumatic stress disorder (PTSD) with osanetant Osanetant targets a distinct group of brain cells in a region of the brain that control...
NEWTON, Mass. and GENEVA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief) today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Acer for U...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023